Your session is about to expire
← Back to Search
The Use of Fibroscan to Assess Liver Fibrosis in Patients With Cardiac Pacemakers
N/A
Waitlist Available
Led By Lawrence Worobetz, MD
Research Sponsored by University of Saskatchewan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
-Any outpatient undergoing routine pacemaker interrogation at pacemaker clinic
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing if FibroScan, a device that uses sound waves to check for liver damage, is safe for patients with chronic liver disease who have pacemakers or ICDs. The study aims to ensure that using FibroScan does not interfere with these implanted heart devices. FibroScan is a non-invasive device that uses sound waves to measure liver stiffness and has been shown to be reliable for assessing liver fibrosis and cirrhosis.
Eligible Conditions
- Non-invasive Indices to Predict Hepatic Fibrosis in BA Patients.
- Liver Cirrhosis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: FibroscanExperimental Treatment1 Intervention
Fibroscan under simultaneous cardiac monitoring
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fibroscan
2016
N/A
~1140
Find a Location
Who is running the clinical trial?
University of SaskatchewanLead Sponsor
257 Previous Clinical Trials
155,891 Total Patients Enrolled
Lawrence Worobetz, MDPrincipal InvestigatorUniversity of Saskatchewan